Publications by authors named "Asami Nukui"
Eribulin is widely used to treat metastatic breast cancer (BC). Higher neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are associated with higher mortality in several cancer types. However, the association between BC prognosis and peripheral immune status remains controversial.
View Article and Find Full Text PDFArticle Synopsis
- Collagen disorders are chronic autoimmune diseases, and their relationship with breast cancer risk is uncertain; this study focused on the outcomes of 25 women with both conditions.
- The study reviewed patient data, revealing that most had specific types of collagen disorders, and the majority received immunosuppressive treatments.
- Key findings showed that these patients had higher Ki-67 levels (indicating faster cancer cell growth) and lower rates of recurrence-free survival (RFS) and overall survival (OS) compared to a control group, suggesting the need for close follow-up for these patients.
Vimentin is a stable mesenchymal immunohistochemical marker and is widely recognized as a major marker of mesenchymal tumors. The purpose of the present study was to investigate if the vimentin expression status might serve as a significant predictor of outcomes in patients with invasive breast carcinoma of no special type (IBC-NST) and to investigate, by comprehensive RNA sequencing analyses, the mechanisms involved in the heightened malignant potential of vimentin-positive IBC-NSTs. This study, conducted using the data of 855 patients with IBC-NST, clearly identified vimentin expression status as a very important independent biological parameter for accurately predicting the outcomes in patients with IBC-NST.
View Article and Find Full Text PDFEarly HER2-positive breast cancer arising from a fibroadenoma: a case report.
Oxf Med Case Reports
September 2021
Breast cancer arising from fibroadenoma (FA) is rare, in which almost all reported cases are human epidermal growth factor receptor 2 (HER2)-negative. This is the first report to describe a case of HER2-positive breast cancer arising from FA that was treated with chemotherapy plus anti-HER2 therapy. In this early case, upfront surgery outcomes guided the selection of appropriate systemic therapy.
View Article and Find Full Text PDFOccult breast cancer is rare in practice. We studied the clinical outcomes of 5 occult breast cancers, including 2 with Luminal and 3 with non-Luminal subtypes, for which the primary site was not detected in the breast-by-breast MRI. The percentage of occult breast cancers that we encountered at our hospital was 0.
View Article and Find Full Text PDFArticle Synopsis
- Granulomatous mastitis is a rare and benign breast condition linked to chronic inflammation, often with an unknown cause, hence it's called idiopathic granulomatous mastitis (IGM).
- Diagnostic imaging techniques like ultrasound and mammography may not always distinguish between benign and malignant tumors, making biopsies necessary for accurate diagnosis.
- The study reports on three IGM cases post-breast conserving surgery in cancer patients, emphasizing the need for tumorectomy when biopsy results are inconclusive, which may help guide future management of similar cases.
Article Synopsis
- The patient had previously undergone a total mastectomy and received combined therapy, including bevacizumab and paclitaxel, followed by radiotherapy for metastases.
- After developing severe dysphagia, an endoscopy revealed significant stenosis, which was treated with balloon dilatations, leading to improvement in her swallowing abilities; the stenosis was likely exacerbated by wound healing effects of bevacizumab in addition to radiation damage.